Nefrología
Podocitos y enfermedad de Fabry (Revisión)
Referencias
1.-
Altarescu G, Elstein D. Fabry disease in an oligosymptomatic male. IMAJ, 2011, 13:
191–192
2.- Tondel
C, Bostad L, Kampevold K, Egil B, Houge G, Svartad E. Agalsidase benefits renal
histology in young patients with Fabry Disease. J Am Soc Nephrol. 2013; 25:
137-148
3.-
Warnock DG. Fabry Disease. Renal aspects of Fabry Disease. Nephrology. 2003; 1(6):802-807
4.-
Politei JM, Cabello JF, Villalobos J, Valadez G, Loaeza A, Linares A, Martins
AM. Enfermedad de Fabry: Nuevos conceptos en su historia natural, evolución y
tratamiento, en relación a los hallazgos del Registro Fabry. Nefrologia,
Diálisis y Transplante. 2009; 29(4):145-152
5.-
Villalobos J, Politei JM, Martins AM, Cabrera G, Amartino H, Lemay R, Ospina S.
Fabry Disease in Latin America: data from the Fabry Registry. JIMD Rep. 2013; 8:
91-99
6.- Keating GM. Simpson
D. Agalsidase Beta: a review of its use in the management of Fabry disease.
Drugs. 2007; 67 (3): 435-455
7.-
Montero N, Soler MJ, Pascual MJ, Barrios C, Márquez E, Rodríguez E, Berrada A, et
al. Correlación entre el cociente proteína/creatinina en orina esporádica y las
proteínas en orina de 24 horas. Nefrologia. 2012; 32(4):494-501
8.-
Carrol M, Temte J. Proteinuria in Adults: A Diagnostic Approach. Am FamPhysician.
2000; 62 (6):1333-1341
9.-
Gubler MC, Lenoir G, Grünfeld JP, Ulmann A, Droz D, Habib R. Early renal
changes in hemizygous and heterozygous patients with Fabry´s disease. KidneyInt.
1978; 13:223-235
10.-
Torra R, Ballarín J. La enfermedad de Fabry. Nefrologia. 2003; 23 (1):84-89
11.- Babelova
A, Jausen F, Sander K, Löhn M, Schäfer L, Fork C, Ruetten H , et al. Activation
of Rac-1 y RhoA contributes to podocytes injury in chronic kidney disease. PLoS
ONE. 2013; 8(11): e80328
12.-
Ortiz A, Marrón B, Ramos A. El destino de los podocitos en las nefropatías
proteinuricas. Nefrologia. 2002; 23 (5):425-430
13.- Li Y,
Kang YS, Dai C, Kiss LP, Wen X, Liu Y. Epithelial to mesenchymal transition is
a potential leading to podocytes dysfunction and proteinuria. Am J Med. 2008; 172(2):
299-308
14.- Doné
SC,Takemoto M,He L ,Sun Y ,Hultenby K ,Betsholtz
C,Tryggvason K. Nephrin is involved in podocyte maturation but not
survival during glomerular development. KidneyInt. 2008; 73:697–704
15.-
Reidy K, Susztak K. Epithelial-Mesenchymal transition and podocyte loss in
diabetic kidney disease. AmJKidneyDis. 2009; 54 (4): 590-599
16.- Chen
S, Meng XF, Zhang C. Role of NADPH oxidase-mediated reactive oxygen species in podocyte
injury. BiomedRes Int. 2013; ID 839761, 7 pages http://dx.doi.org/10.1155/2013/839761
17.- Suzuki
T, Matsusaka T, Nakayama M, Asano T, Watnabe T, Ichicawa I, Nagata M. Genetic
podocyte linage reveals progressive podocytopenia with parietal cell hyperplasia
in a murine model of cellular/collapsing focal segmental glomerulosclerosis. J
Path. 2009;174, (5):1675-1682.
18.-
Barisoni L, Kriz W, Mundel P, D´Agasti V. The dysregulated podocyte phenotype:
a novel concept in the pathogenesis of collapsing idiopathic focal segmental
glomerulosclerosis ans HIV-associated nephropathy. J Am Soc Nephrol 1999;
10:51-61
19.-
Pippin JW, Durvasula R, Petermann A, Hiromura K, Couser WG, Shankland SJ,. DNA
damage is a novel response to sublytic complement C5b-9-induced injury in
podocytes. J Clin Invest 2003; 111:877-885.
20.-Biancini GB, Vanzin CS, Rodriguez DB, Deon
M, Ribas GS, Barschak AG, Manfredini V, et al. Globotriaosylceramide is
correlated with oxidative stress and inflammation in Fabry patients treated
with enzyme replacement therapy. Biochim BiophysActa. 2012;1822: 226-232
21.- Brignull
L M, Czimmerer Z, Saidi H, Daniel B,
Villela I, Bartlett N, Johnston S, Meira L, Nagy L, Nohturfft. Reprogramming of lysosomal gene expression by
interleukin-4 and Stat 6 . BMC Genomics 2013; 14:853
22.- Lu
Y, Hao Bai-Xia, Graeff R, Wong CWM, Wu T, Yue J. Two pore channel 2 (TPC2)
inhibits autophagosomal-lysosomal fusion by alkalinizing lysosomal pH. J Bio Chem 2013; 288 (33): 24247–24263.
23.- Liebau
MC., Braun F, Hopker K, Weitbrecht C, Bartels V, Muller RU¨ ller, Brodesser S, et
al. Dysregulated autophagy contributes to podocyte damage in Fabry’s Disease
PLoS ONE 2013;8(5): e63506
24.-
Vernon PJ. and Tang D. Eat-Me: Autophagy, Phagocytosis, and Reactive Oxygen
Species Signaling.Antioxid Redox Signal.2013;18(6):677-91
25.-
Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R, Kaneski CR. Globotriaosylceramide induces
oxidative stress and up-regulates cell adhesion molecule expression in Fabry
disease endotelial cells. Mol Genet Metab. 2008; 95(3):163–168,
doi:10.1016/j.ymgme.06.016.
26.- Sanchez-Niño
M, Sans A, Carrasco S, Saleem M, Mathieson P, Valdivielso J, et al. Globotriaosylsphingosine
actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol.
Dial. Transplant. (2011) 26 (6): 1797-1802.
27.-
Prabakaran T, Nielsen R, Larsen JV, Sørensen SS, Feldt-Rasmussen U, Saleem MA,
Petersen CM et al. Receptor-mediated endocytosis of α-galactosidase A in human
podocytes in Fabry disease. PLoS ONE.2011;
6(9):e25065
28.-
Zhang A, Huang S. Progress in Pathogenesis of Proteinuria. Int J Nephrol 2012;
2012 Article ID 314251, 14 pages, http://dx.doi.org/10.1155/2012/314251
|